Key Highlights

  • Smith & Nephew plc (LSE:SN.) opened September in the Debt market rather than the Equity market. On 9 September 2026 the FTSE 100 medical technology group priced US$700 million of 5.750% notes due 11 September 2036, confirming the deal to the London Stock Exchange the next morning.
  • The operating backdrop was set on 4 August, when first-half Revenue came in at US$3,097 million, up 2.3% underlying and 4.6% as reported. Trading profit rose 8.1% to US$566 million and the trading profit Margin improved 60 basis points to 18.3%, helped by a trading gross margin up 60 basis points at 71.1%.
  • The bond sale is one half of a paired transaction. On 8 September Smith & Nephew announced a cash tender offer for up to US$250 million in aggregate principal amount of its 2.032% senior notes due 14 October 2030, of which US$900 million is in issue.
  • Three identified headwinds shape the second half. Chinese volume-based procurement is expected in the period, with a full-year profit impact put at US$15 million to US$20 million.
  • Tender results after 15 September will show how much 2030 paper bondholders surrendered, and the fourth-quarter LANDMARK cementless knee launch tests whether the portfolio gap that cost the group US knee share can be closed.

A week spent with lenders rather than shareholders

Smith & Nephew plc (LSE:SN.) opened September in the debt market rather than the equity market. On 9 September 2026 the FTSE 100 medical technology group priced US$700 million of 5.750% notes due 11 September 2036, confirming the deal to the London Stock Exchange the next morning.

Pricing terms filed with the US Securities and Exchange Commission show the notes were sold at 99.154% of principal for a Yield to Maturity of 5.863%, 103 basis points over the comparable Treasury, raising net proceeds of US$690.9 million.

What the $250 million tender offer actually is

The bond sale is one half of a paired transaction. On 8 September Smith & Nephew announced a cash tender offer for up to US$250 million in aggregate principal amount of its 2.032% senior notes due 14 October 2030, of which US$900 million is in issue. This is Liability management in debt securities, not a share repurchase. The company is offering cash to holders of its own bonds, priced off a fixed spread of 55 basis points over a 2031 Treasury benchmark.

The offer prices and expires on 15 September 2026, settles on 18 September, and was conditional on completion of the new 2036 notes offering. The deadline has not passed, so the amount accepted has not been disclosed.

The stated purpose is to "proactively manage the Company's debt portfolio and to extend the average maturity profile" of its obligations. The arithmetic is plain: Smith & Nephew is retiring paper costing 2.032% a year for paper costing 5.750%, and buying roughly six extra years of maturity.

Half-year results: profit ran ahead of revenue

The operating backdrop was set on 4 August, when first-half revenue came in at US$3,097 million, up 2.3% underlying and 4.6% as reported. Trading profit rose 8.1% to US$566 million and the trading profit margin improved 60 basis points to 18.3%, helped by a trading gross margin up 60 basis points at 71.1%. Operating profit was US$448 million, up 4.3%, with Basic Earnings Per Share of 35.6 cents and adjusted earnings per share of 47.7 cents, up 11.0%.

Much of that progress was self-generated: US$130 million of efficiency savings landed in the half, and the full-year target rose to around US$200 million from around US$150 million. Guidance then moved two ways. Underlying revenue growth for 2026 was cut to around 4% from around 6%, while other targets held, including around 8% trading profit growth excluding acquisitions and around US$800 million of free cash flow.

Three franchises, three trajectories

The three franchises are not moving together. Orthopaedics, the largest at US$1,213 million of first-half revenue, saw underlying revenue fall 1.0% in the second quarter, with US knee implants down 7.2% and US hip implants down 1.5%. Sports Medicine and ENT delivered US$1,017 million and 8.6% underlying growth in the quarter, while Advanced Wound Management contributed US$867 million, down 2.1%.

Chief executive Deepak Nath addressed the divergence in the results statement: "The Group navigated some challenges in the second-quarter. Sports Medicine continued to perform strongly, but Orthopaedics was impacted by temporary headwinds in US Hip Implants and ongoing challenges in US Knee Implants ahead of new product introductions." Changes made under the 12-Point Plan, he added, "have made the Group more resilient".

Dividend, buyback and the balance sheet

The interim Dividend was set at 15.6 cents per share, a 4.0% increase, in line with the policy of paying 40% of the prior full-year distribution. A US$500 million buyback announced in May 2026 had US$216 million settled by 3 August: a commenced and partly executed programme, not a fresh authorisation.

Net debt stood at US$3,019 million at the half year, against US$2,759 million at end-2025, or 1.8 times adjusted EBITDA. Free Cash Flow of US$231 million was 5.2% lower, reflecting Capital Expenditure that included a new UK wound care facility. The refinancing moves part of the 2030 maturity out to 2036 without materially changing gross borrowings.

Strategy, and the Shareholder on the register

In December 2025 Smith & Nephew replaced the 12-Point Plan with a strategy branded RISE, built on four pillars: Reach, Innovate, Scale and Execute. Its 2028 targets are 6 to 7% underlying revenue CAGR, 9 to 10% trading profit CAGR, free cash flow above US$1 billion and post-tax return on invested capital of 12 to 13%. In January 2026 it completed the purchase of Integrity Orthopaedics, developer of the Tendon Seam rotator cuff repair system, for US$225 million upfront and up to US$450 million with milestones.

That strategy is being pursued with an activist investor on the register. A notification on 12 August 2026 showed Cevian Capital holding 14.21% of voting rights. Press reports in 2024 and 2025 said some shareholders had urged the board to consider separating Orthopaedics; management has said it would weigh alternatives if the division did not improve. No strategic review or separation has been announced, and RISE retains all three franchises. Separately, chief financial officer John Rogers resigned on 19 August for a US role, leaving on 30 September, with group controller Pierre Palassian appointed interim CFO.

Pressure points and competition

Three identified headwinds shape the second half. Chinese volume-based procurement is expected in the period, with a full-year profit impact put at US$15 million to US$20 million. Changes to US reimbursement for skin substitutes should land at the upper end of a guided US$20 million to US$40 million range. US tariffs, by contrast, were broadly neutral to first-half profit growth once refunds were counted.

In orthopaedics Smith & Nephew remains the smaller player against Stryker, Zimmer Biomet and Johnson & Johnson MedTech; it faces Arthrex in sports medicine and ConvaTec and Molnlycke in wound care. UK stock market sentiment has been unforgiving: the shares traded around 1,025.5p in mid-September for a Market Value of roughly £8.6 billion, having touched a 52-week low of 1,013.5p on 9 September against a high of 1,429.5p a year earlier.

What to watch next

Tender results after 15 September will show how much 2030 paper bondholders surrendered, and the fourth-quarter LANDMARK cementless knee launch tests whether the portfolio gap that cost the group US knee share can be closed. For anyone following FTSE 100 stocks in medical technology, the bond work tidies the maturity profile at a higher coupon; whether RISE converts an 18.3% first-half margin into the 2028 growth targets will be settled by product cycles, not by treasury.